ClinicalTrials.gg
CompletedNCT01926782Updated Mar 21, 2017Results posted

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

A Phase 3 interventional study of Placebo (for alirocumab) and Alirocumab in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 83 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-21.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
803
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
6th of 43
803 · median 107
Started
2013
with 5 others
Phase 3
20 of 43
none open now
Registered
23rd of 43
by date
Lead sponsor
11 of 43
Regeneron Pharmaceuticals

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 6th largest by enrollment, is one of 6 that started in 2013, is one of 20 in phase 3, and was the 23rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4 weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a calibrator.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women > age 18 or legal age of majority with elevated LDL-C
  2. Patients not having adequate control of their hypercholesterolemia based on their individual level of CVD risk
  3. Willing and able to comply with clinic visits and study-related procedures
  4. Provided signed

Exclusion criteria

Exclusion Criteria:

  1. Recent (within 3 months prior to the screening visit) myocardial infarction, unstable angina leading to hospitalization, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), uncontrolled cardiac arrhythmia, stroke, , carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease
  2. Known history of positive test for (HIV)
  3. Any abnormality identified at the time of screening that in the judgment of the investigator or any sub-investigator would preclude safe completion of the study or constrain assessment of endpoints, such as major systemic diseases or participants with short .
  4. Participants considered by the investigator or any sub-investigator to be inappropriate for this study (e.g, geographic or social), actual or anticipated, that the investigator felt would restrict or limit the participant's participation for the duration of the study.
  5. Certain laboratory findings obtained during the screening period

The information listed above is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial and not all inclusion/ exclusion criteria are listed.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
803 participants (actual)

Study arms

  • Placebo comparator
    Placebo Q2W

    Two subcutaneous (SC) injections of placebo (for alirocumab) Q2W with or without stable statin therapy for 48 weeks.

    Drug: Placebo (for alirocumab) · Drug: Statin

  • Experimental
    Alirocumab 75 mg/ Up 150 mg Q2W

    One SC injection of each Alirocumab 75 mg and placebo Q2W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.

    Drug: Placebo (for alirocumab) · Drug: Alirocumab · Drug: Statin

  • Experimental
    Alirocumab 300 mg/ Up 150 mg Q4W

    Two SC injections of Alirocumab 150 mg Q4W alternating with two SC injections of placebo Q4W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.

    Drug: Placebo (for alirocumab) · Drug: Alirocumab · Drug: Statin

Interventions

  • DrugPlacebo (for alirocumab)

    Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.

  • Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.

    Also known as: SAR236553, REGN727, Praluent

  • DrugStatin

    Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 24 and at averaged Week 21 to 24 from MMRM including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects without concomitant statin therapy): all randomized subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on- or off-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  2. Percent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis)

    Adjusted least squares (LS) means and standard errors at Week 24 and at averaged Week 21 to 24 were obtained from a mixed effect model with repeated measures (MMRM) model to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in this model (ITT analysis). ITT population (subjects with concomitant statin therapy): all randomized subjects who received concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on- or off-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis). Modified ITT (mITT) population (subjects with or without concomitant statin therapy): all randomized and treated subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  2. Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis). Modified ITT (mITT) population (subjects with or without concomitant statin therapy): all randomized and treated subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  3. Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  4. Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  5. Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - On-treatment Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  6. Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - On-treatment Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  7. Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  8. Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  9. Percent Change From Baseline in Apo B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  10. Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  11. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on- or off-treatment (non-HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  12. Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on- or off-treatment (non-HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  13. Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). Subjects of the mITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on-treatment (non-HDL-C mITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  14. Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). Subjects of the mITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on-treatment (non-HDL-C mITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  15. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Total-C value on- or off-treatment (Total-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  16. Percent Change From Baseline in Total-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Total-C value on- or off-treatment (Total-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  17. Percent Change From Baseline in Apo B at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo B ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  18. Percent Change From Baseline in Apo B at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo B ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  19. Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Non-HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  20. Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Non-HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  21. Percent Change From Baseline in Total-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Total-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  22. Percent Change From Baseline in Total-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Total-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  23. Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL (Without Concomitant Statin Therapy) at Week 24 - ITT Analysis

    Very high CV risk: history of documented coronary heart disease (CHD) or CHD risk equivalent. High CV risk: calculated 10-year fatal CVD risk score ≥5%, moderate chronic kidney disease, type 1/type 2 diabetes mellitus (DM) without target organ damage, or heFH not meeting definition of very high risk. Moderate CV risk: calculated 10-year fatal CVD risk score ≥1 \&\<5%. CHD risk equivalent: peripheral arterial disease, ischemic stroke, transient ischemic attack, abdominal aortic aneurysm, carotid artery(CA)occlusion\>50%, carotid endarterectomy/CA stent procedure, renal artery stenosis/stent procedure, type 1/type 2 DM with target organ damage. Adjusted percentages at Week 24 obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment included in imputation model. ITT population (subjects with or without concomitant statin therapy).

    Time frame: Up to Week 24

  24. Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (With Concomitant Statin Therapy) at Week 24 - ITT Analysis

    Very high CV risk: history of documented coronary heart disease (CHD) or CHD risk equivalent. High CV risk: calculated 10-year fatal CVD risk score ≥5%, moderate chronic kidney disease, type 1/type 2 diabetes mellitus (DM) without target organ damage, or heFH not meeting definition of very high risk. Moderate CV risk: calculated 10-year fatal CVD risk score ≥1 \&\<5%. CHD risk equivalent: peripheral arterial disease, ischemic stroke, transient ischemic attack, abdominal aortic aneurysm, carotid artery(CA)occlusion\>50%, carotid endarterectomy/CA stent procedure, renal artery stenosis/stent procedure, type 1/type 2 DM with target organ damage. Adjusted percentages at Week 24 obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment included in imputation model. ITT population (subjects with or without concomitant statin therapy).

    Time frame: Up to Week 24

  25. Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL(2.59 mmol/L) (Without Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: Up to Week 24

  26. Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL(1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL(2.59 mmol/L) (With Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: Up to Week 24

  27. Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: Up to Week 24

  28. Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: Up to Week 24

  29. Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: Up to Week 24

  30. Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: Up to Week 24

  31. Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  32. Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  33. Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  34. Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  35. Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline HDL-C value on- or off-treatment (HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  36. Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline HDL-C value on- or off-treatment (HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm

    Time frame: From Baseline to Week 24

  37. Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  38. Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  39. Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  40. Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  41. Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  42. Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  43. Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (subjects with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo A1 value on- or off-treatment (Apo A1 ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  44. Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (subjects with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo A1 value on- or off-treatment (Apo A1 ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 24

  45. Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo A1 ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

  46. Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo A1 ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

    Time frame: From Baseline to Week 12

07

Results

Posted Mar 21, 2017

Participant flow

The study was conducted at 97 sites in 8 countries. A total of 1491 subjects were screened between September 2013 and April 2014, 688 of whom were screen failures. Screen failures were mainly due to inclusion criteria not met.

Participant flow — Overall Study
MilestonePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant StatinPlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Started157783127337146
Treated157783127237146
Completed 24 weeks treatment period137682855831120
Completed129652725329105
Not completed28134020841
Withdrew: Participant moved201103
Withdrew: Physician decision021100
Withdrew: Other than specified23512411
Withdrew: Adverse event134174314
Withdrew: Poor compliance to protocol538016
Withdrew: Randomized and not treated000100
Withdrew: Withdrawal by subject618105
Withdrew: Related to study drug administration000002

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 24 and at averaged Week 21 to 24 from MMRM including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects without concomitant statin therapy): all randomized subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on- or off-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
At Week 24-0.3 ± 2.7-50.2 ± 3.7-52.7 ± 1.9
At averaged Week 21 to 24-1.6 ± 2.6-54 ± 3.6-56.9 ± 1.8
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -52.4 · 97.5% CI -59.8 to -45.0
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -55.2 · 97.5% CI -62.3 to -48.1
PrimaryPercent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis)

Adjusted least squares (LS) means and standard errors at Week 24 and at averaged Week 21 to 24 were obtained from a mixed effect model with repeated measures (MMRM) model to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in this model (ITT analysis). ITT population (subjects with concomitant statin therapy): all randomized subjects who received concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on- or off-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis)
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
At Week 24-0.1 ± 2.3-51.6 ± 3.3-58.8 ± 1.6
At averaged Week 21 to 240.8 ± 2.0-57.9 ± 2.8-65.8 ± 1.4
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -58.7 · 97.5% CI -65.0 to -52.4
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = < 0.0001 (Threshold for significance ≤ 0.025) · Ls mean difference: -65 · 97.5% CI -70.4 to -59.5
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis). Modified ITT (mITT) population (subjects with or without concomitant statin therapy): all randomized and treated subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis-0.4 ± 2.0-54.6 ± 2.8-59.4 ± 1.4
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -59.0 · 97.5% CI -64.6 to -53.4
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis). Modified ITT (mITT) population (subjects with or without concomitant statin therapy): all randomized and treated subjects who did not receive concomitant statin therapy, with one baseline and at least one post-baseline calculated LDL-C value on-treatment. Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis-0.3 ± 2.1-55.1 ± 3.0-62.3 ± 1.5
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -62.0 · 97.5% CI -67.7 to -56.2
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis0.3 ± 2.1-51.8 ± 2.9-58.4 ± 1.4
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -58.7 · 97.5% CI -64.5 to -53.0
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis1.1 ± 2.2-45.3 ± 3.1-55.3 ± 1.5
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -56.3 · 97.5% CI -62.3 to -50.3
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - On-treatment Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - On-treatment Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - On-treatment Analysis-0.5 ± 2.0-53.9 ± 2.7-60.0 ± 1.4
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -59.5 · 97.5% CI -65.0 to -54.1
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - On-treatment Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - On-treatment Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - On-treatment Analysis1.4 ± 1.9-47.3 ± 2.8-58.0 ± 1.4
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -59.4 · 97.5% CI -64.8 to -54.0
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis-0.7 ± 2.3-39.0 ± 3.3-40.2 ± 1.6
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -39.5 · 97.5% CI -45.8 to -33.1
SecondaryPercent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis3.1 ± 1.8-36.7 ± 2.6-45.1 ± 1.3
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -48.2 · 97.5% CI -53.2 to -43.2
SecondaryPercent Change From Baseline in Apo B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Apo B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis-0.3 ± 2.0-42.0 ± 2.7-44.8 ± 1.4
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -44.5 · 97.5% CI -49.9 to -39.1
SecondaryPercent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo B value on- or off-treatment (Apo B ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis3.1 ± 1.7-38.3 ± 2.5-47.2 ± 1.2
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -50.3 · 97.5% CI -55.0 to -45.6
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on- or off-treatment (non-HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis-0.3 ± 2.5-43.6 ± 3.4-43.3 ± 1.7
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -43.0 · 97.5% CI -49.9 to -36.2
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on- or off-treatment (non-HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis0.3 ± 1.9-41.6 ± 2.7-49.7 ± 1.3
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -50.0 · 97.5% CI -55.3 to -44.8
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). Subjects of the mITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on-treatment (non-HDL-C mITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis0.1 ± 2.1-47.2 ± 2.8-48.9 ± 1.4
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -49.0 · 97.5% CI -54.8 to -43.3
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). Subjects of the mITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline non-HDL-C value on-treatment (non-HDL-C mITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis0.2 ± 1.8-44.4 ± 2.5-52.6 ± 1.2
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -52.8 · 97.5% CI -57.6 to -47.9
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Total-C value on- or off-treatment (Total-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis-1.9 ± 1.9-32.5 ± 2.6-33.3 ± 1.3
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -31.4 · 97.5% CI -36.6 to -26.3
SecondaryPercent Change From Baseline in Total-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline Total-C value on- or off-treatment (Total-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Total-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis-0.8 ± 1.4-30.0 ± 2.0-35.8 ± 1.0
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -35.0 · 97.5% CI -38.9 to -31.1
SecondaryPercent Change From Baseline in Apo B at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo B ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Apo B at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis-2.3 ± 1.7-40.8 ± 2.5-46.4 ± 1.3
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -44.1 · 97.5% CI -49.0 to -39.2
SecondaryPercent Change From Baseline in Apo B at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo B ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Apo B at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis3.6 ± 1.8-33.0 ± 2.5-41.2 ± 1.3
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -44.8 · 97.5% CI -49.7 to -39.9
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Non-HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis-0.4 ± 1.8-45.8 ± 2.5-49.9 ± 1.3
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -49.5 · 97.5% CI -54.5 to -44.6
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Non-HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis0.6 ± 1.9-37.4 ± 2.7-46.5 ± 1.3
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -47.1 · 97.5% CI -52.2 to -42.0
SecondaryPercent Change From Baseline in Total-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Total-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Total-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis-1.0 ± 1.4-33.4 ± 2.0-37.4 ± 1.0
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -36.4 · 97.5% CI -40.4 to -32.4
SecondaryPercent Change From Baseline in Total-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Total-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Total-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis-0.1 ± 1.3-26.5 ± 1.9-32.9 ± 1.0
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: -32.8 · 97.5% CI -36.5 to -29.1
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL (Without Concomitant Statin Therapy) at Week 24 - ITT Analysis

Very high CV risk: history of documented coronary heart disease (CHD) or CHD risk equivalent. High CV risk: calculated 10-year fatal CVD risk score ≥5%, moderate chronic kidney disease, type 1/type 2 diabetes mellitus (DM) without target organ damage, or heFH not meeting definition of very high risk. Moderate CV risk: calculated 10-year fatal CVD risk score ≥1 \&\<5%. CHD risk equivalent: peripheral arterial disease, ischemic stroke, transient ischemic attack, abdominal aortic aneurysm, carotid artery(CA)occlusion\>50%, carotid endarterectomy/CA stent procedure, renal artery stenosis/stent procedure, type 1/type 2 DM with target organ damage. Adjusted percentages at Week 24 obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment included in imputation model. ITT population (subjects with or without concomitant statin therapy).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL (Without Concomitant Statin Therapy) at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL (Without Concomitant Statin Therapy) at Week 24 - ITT Analysis9.484.978.9
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.025.) · Odds ratio (or): 68.0 · 97.5% CI 20.9 to 221.0Multiple imputation approach followed by logistic regression model.
SecondaryPercentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (With Concomitant Statin Therapy) at Week 24 - ITT Analysis

Very high CV risk: history of documented coronary heart disease (CHD) or CHD risk equivalent. High CV risk: calculated 10-year fatal CVD risk score ≥5%, moderate chronic kidney disease, type 1/type 2 diabetes mellitus (DM) without target organ damage, or heFH not meeting definition of very high risk. Moderate CV risk: calculated 10-year fatal CVD risk score ≥1 \&\<5%. CHD risk equivalent: peripheral arterial disease, ischemic stroke, transient ischemic attack, abdominal aortic aneurysm, carotid artery(CA)occlusion\>50%, carotid endarterectomy/CA stent procedure, renal artery stenosis/stent procedure, type 1/type 2 DM with target organ damage. Adjusted percentages at Week 24 obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment included in imputation model. ITT population (subjects with or without concomitant statin therapy).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (With Concomitant Statin Therapy) at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (With Concomitant Statin Therapy) at Week 24 - ITT Analysis22.282.585.2
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.025.) · Odds ratio (or): 25.6 · 97.5% CI 13.7 to 47.8
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL(2.59 mmol/L) (Without Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL(2.59 mmol/L) (Without Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis
percentage of participantsPlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL(2.59 mmol/L) (Without Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis11.393.088.6
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.025.) · Odds ratio (or): 280.2 · 97.5% CI 56.7 to 1385.7Multiple imputation approach followed by logistic regression model.
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL(1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL(2.59 mmol/L) (With Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL(1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL(2.59 mmol/L) (With Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis
percentage of participantsPlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL(1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL(2.59 mmol/L) (With Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis22.586.489.5
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.025.) · Odds ratio (or): 41.3 · 97.5% CI 20.3 to 83.8
SecondaryPercentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis3.357.762.0
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.025.) · Odds ratio (or): 90.6 · 97.5% CI 16.5 to 498.3
SecondaryPercentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
percentage of participantsPlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis10.974.480.4
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.025.) · Odds ratio (or): 49.5 · 97.5% CI 23.4 to 104.4
SecondaryPercentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsPlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis2.161.770.4
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.025.) · Odds ratio (or): 297.1 · 97.5% CI 27.9 to 3160.6
SecondaryPercentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection). mITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsPlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis10.877.484.8
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.025.) · Odds ratio (or): 77.7 · 97.5% CI 34.1 to 176.8
SecondaryPercent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis6.4 ± 3.4-14.0 ± 4.8-21.3 ± 2.4
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.025.) · Adjusted mean difference: -27.7 · 97.5% CI -37.0 to -18.3
SecondaryPercent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis9.8 ± 2.4-16.9 ± 3.3-19.3 ± 1.6
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.025.) · Adjusted mean difference: -29.1 · 97.5% CI -35.5 to -22.7
SecondaryPercent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis-5.5 ± 3.3-26.9 ± 4.7-28.9 ± 2.3
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.025.) · Adjusted mean difference: -23.5 · 97.5% CI -32.4 to -14.5
SecondaryPercent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis7.0 ± 2.3-12.4 ± 3.2-19.6 ± 1.6
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.025.) · Adjusted mean difference: -26.6 · 97.5% CI -32.8 to -20.4
SecondaryPercent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline HDL-C value on- or off-treatment (HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis-5.3 ± 1.7-0.1 ± 2.42.5 ± 1.2
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = 0.0003 (Threshold for significance ≤ 0.025.) · Ls mean difference: 7.8 · 97.5% CI 3.1 to 12.6
SecondaryPercent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (with or without concomitant statin therapy) with one baseline and at least one post-baseline HDL-C value on- or off-treatment (HDL-C ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis-1.5 ± 1.26.0 ± 1.73.6 ± 0.8
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = 0.0004 (Threshold for significance ≤ 0.025.) · Ls mean difference: 5.1 · 97.5% CI 1.9 to 8.4
SecondaryPercent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis-0.9 ± 1.62.5 ± 2.26.0 ± 1.1
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = 0.0004 (Threshold for significance ≤ 0.025.) · Ls mean difference: 6.9 · 97.5% CI 2.6 to 11.1
SecondaryPercent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. HDL-C ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis0.4 ± 1.27.6 ± 1.85.7 ± 0.9
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = 0.0007 (Threshold for significance ≤ 0.025.) · Ls mean difference: 5.2 · 97.5% CI 1.8 to 8.7
SecondaryPercent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis-1.5 ± 3.4-9.8 ± 4.9-13.4 ± 2.5
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Regression, Robust · p = 0.0042 (Threshold for significance ≤ 0.025.) · Adjusted mean difference: -11.9 · 97.5% CI -21.3 to -2.6
SecondaryPercent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis-0.1 ± 2.4-6.7 ± 3.3-15.2 ± 1.6
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.025.) · Adjusted mean difference: -15.1 · 97.5% CI -21.5 to -8.6
SecondaryPercent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis1.8 ± 3.2-18.3 ± 4.6-12.3 ± 2.3
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Regression, Robust · p = 0.0004 (Threshold for significance ≤ 0.025.) · Adjusted mean difference: -14.1 · 97.5% CI -22.9 to -5.2
SecondaryPercent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis0.5 ± 2.4-7.3 ± 3.5-13.1 ± 1.7
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.025.) · Adjusted mean difference: -13.6 · 97.5% CI -20.3 to -6.9
SecondaryPercent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (subjects with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo A1 value on- or off-treatment (Apo A1 ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis-1.4 ± 1.33.1 ± 1.95.2 ± 0.9
Statistical analysis
  • Placebo Q2W Without Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.025.) · Ls mean difference: 6.6 · 97.5% CI 3.0 to 10.2
SecondaryPercent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Subjects of the ITT population (subjects with or without concomitant statin therapy) with one baseline and at least one post-baseline Apo A1 value on- or off-treatment (Apo A1 ITT population). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis2.9 ± 1.06.5 ± 1.45.5 ± 0.7
Statistical analysis
  • Placebo Q2W With Concomitant Statin vs Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin · Mixed Models Analysis · p = 0.0306 (Threshold for significance ≤ 0.025.) · Ls mean difference: 2.7 · 97.5% CI -0.1 to 5.4Alirocumab 300 mg vs. Placebo
SecondaryPercent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo A1 ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
percent changePlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin
Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis-1.8 ± 1.32.4 ± 1.84.6 ± 0.9
SecondaryPercent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. Apo A1 ITT population (subjects with or without concomitant statin therapy). Alirocumab 75 mg Q2W arm (calibrator arm) was included only to facilitate comparison of results of this study with the results of other studies that used an alirocumab 75 mg Q2W regimen. Hence no statistical comparison was performed for this arm.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis
percent changePlacebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin
Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis2.7 ± 1.06.1 ± 1.46.0 ± 0.7

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 56 post-treatment follow-up visit) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W—33/229 (14.4%)118/229 (51.5%)
Alirocumab 75 mg Q2W/Up 150 mg Q2W—13/115 (11.3%)55/115 (47.8%)
Alirocumab 300 mg Q4W/Up 150 mg Q2W—53/458 (11.6%)229/458 (50%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventPlacebo Q2WAlirocumab 75 mg Q2W/Up 150 mg Q2WAlirocumab 300 mg Q4W/Up 150 mg Q2W
PneumoniaInfections and infestations1/2292/1151/458
Myocardial infarctionCardiac disorders3/2290/1151/458
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders3/2290/1153/458
Angina unstableCardiac disorders2/2290/1152/458
Non-Cardiac chest painGeneral disorders1/2291/1154/458
Angina pectorisCardiac disorders1/2291/1151/458
Cardiac failure chronicCardiac disorders0/2291/1150/458
Ischaemic cardiomyopathyCardiac disorders0/2291/1150/458
Mitral valve incompetenceCardiac disorders0/2291/1150/458
Ventricular tachycardiaCardiac disorders0/2291/1150/458
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlacebo Q2WAlirocumab 75 mg Q2W/Up 150 mg Q2WAlirocumab 300 mg Q4W/Up 150 mg Q2W
Injection site reactionGeneral disorders16/22910/11574/458
Upper respiratory tract infectionInfections and infestations18/2298/11541/458
NasopharyngitisInfections and infestations18/22910/11539/458
DiarrhoeaGastrointestinal disorders17/2294/11525/458
NauseaGastrointestinal disorders15/2297/11519/458
ArthralgiaMusculoskeletal and connective tissue disorders15/2297/11529/458
Back painMusculoskeletal and connective tissue disorders14/2293/11529/458
HeadacheNervous system disorders13/2296/11529/458
SinusitisInfections and infestations11/2294/11528/458
Urinary tract infectionInfections and infestations10/2297/11528/458

Baseline characteristics

All randomized population regardless of concomitant statin therapy.

Age, Continuous
Age, Continuous(years)Placebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant StatinPlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant StatinTotal
Mean61.6 ± 9.760.7 ± 9.161.6 ± 1059.4 ± 10.259.3 ± 11.359.2 ± 10.860.8 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant StatinPlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant StatinTotal
Female5627122332380341
Male10151190401466462
Calculated LDL-C in mg/dL
Calculated LDL-C in mg/dL(mg/dL)Placebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant StatinPlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant StatinTotal
Mean112.1 ± 37.3114.9 ± 36112.4 ± 32.8131 ± 30.4148.4 ± 36.8146.1 ± 33.5122.1 ± 36.9
Calculated LDL-C in mmol/L
Calculated LDL-C in mmol/L(mmol/L)Placebo Q2W With Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant StatinPlacebo Q2W Without Concomitant StatinAlirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant StatinAlirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant StatinTotal
Mean2.903 ± 0.9652.977 ± 0.9332.912 ± 0.853.392 ± 0.7873.842 ± 0.9533.785 ± 0.8683.162 ± 0.956
08

Study locations

83 sites
  • Chandler, Arizona, United States
  • Goodyear, Arizona, United States
  • Carmichael, California, United States
  • Fresno, California, United States
  • West Hills, California, United States
  • Wildomar, California, United States
  • Colorado Springs, Colorado, United States
  • Golden, Colorado, United States
  • Boynton Beach, Florida, United States
  • Jacksonville, Florida, United States
  • Safety Harbor, Florida, United States
  • Atlanta, Georgia, United States
  • Boise, Idaho, United States
  • Meridian, Idaho, United States
  • Chicago, Illinois, United States
  • Gurnee, Illinois, United States
  • Evansville, Indiana, United States
  • Indianapolis, Indiana, United States
  • Iowa City, Iowa, United States
  • Kansas City, Kansas, United States
  • Louisville, Kentucky, United States
  • Monroe, Louisiana, United States
  • Auburn, Maine, United States
  • Methuen, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • St. Louis, Missouri, United States
  • Rochester, New York, United States
  • Farmville, North Carolina, United States
  • Greensboro, North Carolina, United States
  • Greenville, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Wilson, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Marion, Ohio, United States
  • Tulsa, Oklahoma, United States
  • Philadelphia, Pennsylvania, United States
  • Wyomissing, Pennsylvania, United States
  • Knoxville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Orem, Utah, United States
  • Salt Lake City, Utah, United States
  • South Jordan, Utah, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Spokane, Washington, United States
  • Tacoma, Washington, United States
  • Kenosha, Wisconsin, United States
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Victoria, British Columbia, Canada
  • Oshawa, Ontario, Canada
  • Toronto, Ontario, Canada
  • Woodstock, Ontario, Canada
  • Montreal, Quebec, Canada
  • Trois-Rivieres, Quebec, Canada
  • Quebec, Canada
  • Budapest, Becsi ut, Hungary
  • Debrecen, HBM, Hungary
  • Nyiregyhaza, Sz-sz-b_m, Hungary
  • Ajka, Veszprém, Hungary
  • Nagykanizsa, Zala, Hungary
  • Zalaegerszeg, Zala, Hungary
  • Tel Hashomer, IL, Israel
  • Safed, ISR, Israel
  • Ofakim, South, Israel
  • Holon, Israel
  • Tel Hashomer, Israel
  • Skedsmokorset, Akershus, Norway
  • Oslo, Norway
  • Svidnik, Presov, Slovakia
  • Bratislava, SK, Slovakia
  • Bratislava, SR, Slovakia
  • Lucenec, Slovakia
  • Považská Bystrica, Slovakia
  • Worton Grange, Reading, Berkshire, United Kingdom
  • Edgbaston, Birmingham, United Kingdom
  • Llanishen, Cardiff, United Kingdom
  • Choley, Lancashire, United Kingdom
  • Waterloo, Liverpool, United Kingdom
  • Lloyd Street North, Manchester, United Kingdom
  • Glasgow, Scotland, United Kingdom
09

References and documents

Publications

  • Roth EM, Kastelein JJP, Cannon CP, Farnier M, McKenney JM, DiCioccio AT, Brunet A, Manvelian G, Sasiela WJ, Baccara-Dinet MT, Zhao J, Robinson JG. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. J Clin Lipidol. 2020 Sep-Oct;14(5):707-719. doi: 10.1016/j.jacl.2020.07.009. Epub 2020 Jul 25. PubMed 32928709 ↗
  • Muller-Wieland D, Rader DJ, Moriarty PM, Bergeron J, Langslet G, Ray KK, Manvelian G, Thompson D, Bujas-Bobanovic M, Roth EM. Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin. J Clin Endocrinol Metab. 2019 Nov 1;104(11):5253-5262. doi: 10.1210/jc.2018-02703. PubMed 31166599 ↗
  • Roth EM, Moriarty PM, Bergeron J, Langslet G, Manvelian G, Zhao J, Baccara-Dinet MT, Rader DJ; ODYSSEY CHOICE I investigators. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis. 2016 Nov;254:254-262. doi: 10.1016/j.atherosclerosis.2016.08.043. Epub 2016 Aug 31. PubMed 27639753 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Sep 2014 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 2 years 6 months after primary completion. A results delay was requested in Jan 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2013
First posted
Aug 21, 2013
Start
Sep 2013
Primary completionActual
Sep 2014
CompletionActual
Apr 2015
Results delay requested
Jan 24, 2015
Results first posted
Mar 21, 2017
Last update
Mar 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01926782
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Aug 21, 2013
Start date
Sep 2013
Primary completion
Sep 2014
Completion
Apr 2015
Results posted
Mar 21, 2017
Last update
Mar 21, 2017

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion